Prebiopsy steroids & diagnostic yield DLBCL #lymsm - 320 pts - yield unchanged w/ steroids (83% v 81%) - no association w/ dose/duration - no delay in time to treatment - FNA less diagnostic than excisional/incisional - core needle 12% less likely to be diagnostic jamanetwork.com/journals/jam...

ctDNA TRANSFORM #lymsm - MRDneg = longer EFS at all timepoints - more pts achieved MRDneg with liso-cel v SOC - among MRDneg pts liso-cel ⬆️ EFS, PFS, DOR - MRD re-emergence 1 yr: 0/20 liso-cel v 9/15 ASCT - ctDNA prognostic independent of PET Role for ctDNA+PET post-CAR? ascopubs.org/doi/pdf/10.1...

NAVD real-world outcomes #lymsm - 327 pts, med age 37, 24% ≥60 yrs - ORR 94% (CR 86%) - 1-yr PFS 94.5%, OS 99.7% - irAEs in 29% (9% G3+) - febrile neutropenia 10%, infections 25% (10% G3+) RW efficacy mirrors S1826, tho notably⬆️ infections (despite GCSF) & irAEs. pmc.ncbi.nlm.nih.gov/articles/PMC...

Spotlight on Dr. Brad Haverkos, Associate Professor at the University of Colorado, specializing in T/NK-cell lymphoma & immunotherapy. He leads a multidisciplinary clinic and clinical trials program advancing targeted care. Passionate about team-based innovation in lymphoma research.

Mosun/pola R/R MCL #lymsm - 42 pts, 26% prior CAR, 48% TP53mut - ORR 88% (CR 79%) - mPFS 19 mos, mOS 21 mos - prior CAR: ORR 91% (CR 82%) - 43% CRS (all G1-2), 5 G5 AEs, all infection-related Great activity in TP53mut and post-CAR in challenging R/R setting. ashpublications.org/blood/articl...

Come join us on Saturday, May 2 for the @bloodcancerunited.bsky.social 2026 Rocky Mountain Blood Cancer Conference! I'll be speaking about Waldenström macroglobulinemia and novel therapeutic approaches on the horizon. #lymsm #wmsm bloodcancerunited.org/RMBCC26

Stage IA NLPHL outcomes - 779/2243 pts Stage IA - completely resected: better PFS if +RT - unresected: R monotx & ABVD with worse PFS as compared to RT +/- ABVD - not enough N to analyze R-CHOP RT alone great option in both resected & unresected dx. #lymsm ashpublications.org/bloodadvance...

New anatomic classification R/R SCNSL - 162 pts, 42 with both CNS+systemic dx - leptomeningeal dx = inferior OS in MV model - 4 subtypes w/ distinct PFS & OS: parenchymal +/- systemic and LM +/- systemic (see KM curve) Useful schema in future trials. #lymsm onlinelibrary.wiley.com/doi/10.1002/...

Glofitamab CNS penetration @bloodadvances.bsky.social - 8 PCNSL/SCNSL, 7 LBCL, 1 BL - 3/8 CRS (all G1-2), no ICANS - 7/8 response (4 CR, 3 PR) - 2 PCNSL durable CRs - CSF: +glofi with activity in vitro Bridging to CAR for SCNSL or even monotx for PCNSL. #lymsm ashpublications.org/bloodadvance...

Tazemetostat pulled from the market this morning due to secondary malignancy risks seen in the SYMPHONY-1 trial. #lymsm

Many thanks to @onclive.bsky.social for reviewing our #Tandem26 abstract on outcomes of CD20 bispecifics after CD19 CAR in R/R MCL, an analysis from the CUBIC Consortium. #lymsm #tcellrx Abstract link: www.astctjournal.org/article/S266... www.onclive.com/view/real-wo...

Axi-cel can now be used for R/R PCNSL! HT @samyamshon.bsky.social #lymsm #tcellrx

Infx post CD20 bispecifics @bloodadvances.bsky.social - 122 pts - 61% ≥1 infx episode; 37% had Grade 3+ infx!!! (lots of CMV) - 76% cumulative incidence infx at 2 yrs - 8% G5 infx at 1 year Important data (more infx than CAR?); need ppx/IVIG strategies. #lymsm ashpublications.org/bloodadvance...

Hoping I have favor with the kiln deities! #pleasedontbreak #pottery

Elated to be presenting our MAGIC-ONC vascular access appropriateness recommendations in patients with cancer to the @hms-mi.bsky.social consortium today! Be sure to read the full paper published @annalsofim.bsky.social: www.acpjournals.org/doi/10.7326/... #medsky #oncsky cc @davidpaje.bsky.social

CD3xCD20 BsAb CNS lymphoma #ASH25 - 28 pts from CUBIC (22 glofi), 18 active CNSi - 6-mo PFS/OS 44%/81% - active CNSi: ORR 56% (CR 33%) - 67% received combo tx (BTKi, len, IT chemo) Outcomes with active CNSi similar to trials. Need more pts & longer f/u. #lymsm #tcellrx

CNS relapse of LBCL after CAR-T #ASH25 - 1102 pts R/R LBCL: 79% CAR, 21% CIT - 1.6% incidence of CNS relapse after CAR (2.2% CIT cohort) - time from CAR to CNSr 4.7 mo Corroborates known CAR CNS penetration. Upfront CAR if high CNSr risk? #lymsm #tcellrx

3-year f/u STARGLO #ASH25 - glofi-GemOx: mPFS 14 (v 3 mos), mOS 26 (v 13 mos) - in 2L: mPFS 20 (vs 5 mos), mOS NR (vs 14 mos) - 20% G3+ infx AEs in glofi arm Maybe a PFS plateau on KM curves if you squint... #lymsm #tcellrx

Q-TWIST analysis of CARTITUDE-4 @surbhisidanamd.bsky.social #ASH25: 9-13 month gain of quality-adjusted time w/o symptoms/toxicity as compared to SOC, and this includes time with high-grade ICANS. #mmsm #tcellrx

Patients with poor baseline HRQoL in ALPINE trial still had PFS benefit with zanu (vs ibrutinib). #lymsm #ASH25

Spiritual wellness & QoL PROs in acute leukemia #ASH25 - 30 pts, 27% AYA, 53% AML - higher spiritual wellness = better QoL across first 30 days of treatment (at baseline & 30 days) Opportunity to improve QoL/PROs with spiritual support services at diagnosis. #leusm

Time & financial tox work at #ASH25: 66 pts (40 #lymsm, 26 #mmsm) treated with BsAb or CAR-T. ~25% had significant FT at 3 months, and time tox decreased over time. FT & TT both associated with worse QoL & psychological distress.

Glofi+obin 1L HTB FL #ASH25 - 35 pts, 63% FLIPI 3-5 - ORR 100% (CR 88%) - pretx with 4 doses of obinu: 40% any-grade CRS, all G1 except 1 case of G3 - 31% infx (all G1-2) - only 7.5 mo F/U: 8-mo PFS 95% More chemo-free options in 1L FL; need more f/u. #lymsm

Epidemiological data on NLPHL presented at the @ash.hematology.org #ASH25 Annual Meeting. Using a UK-based cancer registry, higher incidence of NLPHL in Black and Asian patients as compared to White patients. 5-year OS and relative survival of >90%. #lymsm #NLPHLsm

More time toxicity work from #ASH25: adults with ALL spent 25% of days over the first year physically interacting with the health care system. Tremendous potential to improve this with novel agents and/or hospital at home care delivery models. #leusm #AYAsm #timetox @ash.hematology.org

Pirto v venetoclax in R/R WM #ASH25 - 91 pts: 64 VEN - MV model:⬇️PFS w/ ven if TP53mut;⬇️MRR & PFS w/ pirto if CXCR4mut - no diff in MRR or PFS between pirto & VEN - transition from BTKi to VEN = 62% IgM rebound (didn't happen w/ pirto) Genetic-based tx decisions in WM! #lymsm

A time toxicity analysis of CAR-T in NHL by Trotier et al. from #ASH25 (using claims data) found a 1-year median of 52 contact days, very similar to our multicenter study. Very promising that we can use claims data to generate these time toxicity data. #lymsm cc @uduranimd.bsky.social

In our study of real-world survival & time toxicity of CAR-T vs BsAb in R/R FL, we found that CAR-T resulted in superior PFS but more time toxicity, with no difference in OS. Over first year, 51-64 physical healthcare contact days with CAR-T vs 36-38 with BsAb. #lymsm www.vumedi.com/video/ash-20...

CU Cancer Center member Ajay Major (@majorajay.bsky.social), MD, MBA, led a study of more than 25,000 long-term childhood cancer survivors, to learn more about their rates of colorectal cancer and what their doctors can do about it ⬇️ https://bit.ly/3MkDl2t

At #ASH25, we presented our patient-reported time toxicity study in 120 pts w/ R/R FL & DLBCL on mosun, glofi & epcor. Mosun & glofi w/⬇️all-cause healthcare visits & hours spent on cancer-related care in past 30 days v epcor. More details in this #thread. #lymsm www.sciencedirect.com/science/arti...

Announcing my #ASHNewsDaily Golden Globule award picks for @ash.hematology.org #ASH25! I gave my awards to the best (shocker) patient-reported outcomes abstracts, including quality of life studies from trials and in real-world practice. #MajorPROsASH ashpublications.org/ashnewsdaily...

Thanks for all the great memories, my #ASH25 friends! Stay in touch, and looking forward to seeing your new abstracts at #ASH26. cc @ash.hematology.org

Our budding PRO researcher Dr. Hofmeister @cuinternalmed.bsky.social in the @cuhematology.bsky.social Major Lab presented her work on quality of life in CTCL at the @ash.hematology.org #ASH25 Annual Meeting. Thread below with our study findings. 🧵 #lymsm

The L-THORs (Lymphoma Translational Health Outcomes Researchers) assemble at #ASH25, presenting work in patient-reported outcomes and time toxicity! 🎉 #lymsm cc @ash.hematology.org

Twins looking sharp!! #ASH25

Hematology twins! @mazietsangmd.bsky.social #ASH25 #fASHion cc @ash.hematology.org

If you want a preview of the CLL17 plenary later today, read my #ASHNewsDaily article where I interview Dr. Othman Al-Sawaf about the study results and time-limited versus indefinite treatment strategies in 1L CLL. #ASH25 #leusm ashpublications.org/ashnewsdaily... @ash.hematology.org

Hey #ASH25: check out my #ASHNewsDaily interviews with Drs. Ferdinandus & Herrera about the HD21 & S1826 trials setting new standards for cHL, and with Drs. Ahmed & Falchi about TRANSCEND & EPCORE FL-1 maximizing remissions in FL. #lymsm ashpublications.org/ashnewsdaily... @ash.hematology.org

Now online: my #ASHNewsDaily article interviewing presenters at this afternoon's 'Innovative Models of Lymphoma' Scientific Program Session (2pm, OCCC, West Hall E2) about the future of lymphoma-mimicking organoids, xenografts, and mice. #ASH25 @ash.hematology.org ashpublications.org/ashnewsdaily...

Happy #ASH25 day! Check out all of this year's #MajorPROsASH, the top 20 best patient-reported outcomes & quality of life abstracts from this year's @ash.hematology.org meeting. Check out the hashtag for details on all the abstracts: bsky.app/hashtag/Majo...

FD mosun in 1L HTB FL #ASH25 - 103 pts - 46/68 elected for maintenance mosun + 1 yr - ORR 87% (CR 64%), 1-yr PFS 86% - 33 d/c'd (mostly d/t PD) - 78% infections, 5 pts with G5 AEs! Need longer f/u & more CRS data. Seems somewhat toxic. #lymsm

5-yr f/u pirto R/R WM #ASH25 - 80 pts, 89% MYD88mut, 22% CXCR4mut, 79% prior cBTKi - ORR 83%, MRR 73%, mDOR 42 mo - mPFS 3 yr, 3-yr OS 67% - RR & PFS similar w/ prior cBTKi Great outcomes in heavily-pretx. Combo w/ pirto (like ven) being explored for FD tx. #lymsm

Pirto+ven R/R WM/LPL #ASH25 - 38 pts, 29 completed 6 cycles (total 24) - ORR 100%, VGPR/CR 56% - lower RR if CXCR4mut, TP53mut, prior cBTKi - 12-mo PFS 94% - MYD88wt pts (n = 2) w/ early PD Great all oral option for MYD88mut R/R WM. #lymsm #wmsm

DRC+/-bortezomib randomized 1L WM #ASH25 - 202 pts - mPFS 57 mos (B-DRC) vs 50 mos (DRC) - no diff TTNT or OS (5-yr OS 89-91%) - much more PN in B arm - 4-mo cum incidence of first response 73% B-DRC (vs 61% DRC) Outcomes very similar to BR. #lymsm

Going to skip pre-tweeting these #ASH25 abstracts because I review them (and interview the presenters!) in my #ASHNewsDaily article coming out on Sunday! #lymsm

1 – #MajorPROsASH – 709 Karmali Liso-cel in R/R MZL: early deterioration in multiple QoL domains by D15. However, by 3 months after liso-cel, QoL rebounds above pre-CAR baseline & sustained until 18 months after liso-cel! Now FDA approved w/ meaningful QoL benefits. #lymsm #ASH25 @ash.hematology.org

Right on the eve of @ash.hematology.org #ASH25: liso-cel approved for R/R MZL after 2+ prior lines of therapy! #lymsm #tcellrx www.fda.gov/drugs/resour...

2 – #MajorPROsASH – 5509 Budde Mosun-pola w/ sig prolonged TTD of phys fxn, #lymsm related sx, and neuropathy vs R-GemOx. Fatigue improved with mosun-pola (no change R-GemOx). Pain improved faster w/ mosun-pola. QoL & PFS improvements in palliative setting. #ASH25 @ash.hematology.org

3 – #MajorPROsASH – 5370 Linton EPCORE FL-1 PROs: Functional QOL + side effect burden initially worsens w/ epco+R2, recovers by C5D1. Otherwise no clinically meaningful worsening in QoL by EOT w/ epco+R2 or R2. Can counsel pts about dynamic QoL changes over time. #ASH25 #lymsm @ash.hematology.org

4 – #MajorPROsASH – 5362 Frustaci Prospective frailty & PROs WM: Nearly all pts w/ at least 1 impaired geri domain. Functional/psychological status & lack of social support significantly associated with inferior QoL. PRO + geri assessment can stratify frailty in WM. #ASH25 #lymsm @ash.hematology.org